SEC Tracker
Get the app

Foundation Medicine

Foundation Medicine Q3 FY17: revenue $42.7M, up 45%

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Foundation Medicine reported for Q3 FY17, the quarter ended Sep 30, 2017, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$42.7M+45% from $29.4M in Q3 FY1610-Q income statement, on EDGAR
  2. Net income−$32.6MAgainst −$31.3M in Q3 FY1610-Q income statement, on EDGAR
  3. Cash and cash equivalents$76.8M−1% from $77.8M in Q3 FY1610-Q balance sheet, on EDGAR

View on EDGAR

Open in the app

Get an email when Foundation Medicine files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (8071) and public float not reported.

  1. BillionToOne BLLN
  2. Burning Rock Biotech BNR
  3. Halberd HALB
  4. Lumexa Imaging Holdings LMRI
  5. MDxHealth MDXH

Data on this page was fetched . The filing on SEC.gov is the record.